Myomo Q4 net loss widens to USD 3.81 million as operating expenses rise 19% to USD 10.56 million

Reuters03-10

Myomo Q4 net loss widens to USD 3.81 million as operating expenses rise 19% to USD 10.56 million

Myomo reported Q4 revenue of USD 11.35 million, down 6%, reflecting a modest decrease in revenue units and a lower average selling price. Q4 operating loss was USD 2.77 million and net loss was USD 3.81 million. FY 2025 revenue rose 26% to USD 40.93 million, while FY net loss was USD 15.57 million. Q4 operating expenses increased 19% to USD 10.56 million, driven primarily by higher sales, clinical and marketing spending, including higher advertising expense. Myomo introduced FY 2026 revenue guidance of USD 43 million to USD 46 million and expects Q1 2026 revenue of USD 9 million to USD 9.5 million as it emphasizes recurring patient sources and reduces reliance on advertising-driven revenue.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Myomo Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202603091606BIZWIRE_USPR_____20260309_BW467133) on March 09, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2618674366?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-10 04:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618674366","market":"us","top_or_hot":-1,"title":"Myomo Q4 net loss widens to USD 3.81 million as operating expenses rise 19% to USD 10.56 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Myomo Q4 net loss widens to USD 3.81 million as operating expenses rise 19% to USD 10.56 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Myomo reported Q4 revenue of USD 11.35 million, down 6%, reflecting a modest decrease in revenue units and a lower average selling price. Q4 operating loss was USD 2.77 million and net loss was USD 3.81 million. FY 2025 revenue rose 26% to USD 40.93 million, while FY net loss was USD 15.57 million. Q4 operating expenses increased 19% to USD 10.56 million, driven primarily by higher sales, clinical and marketing spending, including higher advertising expense. Myomo introduced FY 2026 revenue guidance of USD 43 million to USD 46 million and expects Q1 2026 revenue of USD 9 million to USD 9.5 million as it emphasizes recurring patient sources and reduces reliance on advertising-driven revenue.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/MYO\">Myomo Inc.</a> published the original content used to generate this news brief via Business Wire (Ref. ID: 202603091606BIZWIRE_USPR_____20260309_BW467133) on March 09, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Myomo Q4 net loss widens to USD 3.81 million as operating expenses rise 19% to USD 10.56 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMyomo Q4 net loss widens to USD 3.81 million as operating expenses rise 19% to USD 10.56 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-10 04:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Myomo Q4 net loss widens to USD 3.81 million as operating expenses rise 19% to USD 10.56 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Myomo reported Q4 revenue of USD 11.35 million, down 6%, reflecting a modest decrease in revenue units and a lower average selling price. Q4 operating loss was USD 2.77 million and net loss was USD 3.81 million. FY 2025 revenue rose 26% to USD 40.93 million, while FY net loss was USD 15.57 million. Q4 operating expenses increased 19% to USD 10.56 million, driven primarily by higher sales, clinical and marketing spending, including higher advertising expense. Myomo introduced FY 2026 revenue guidance of USD 43 million to USD 46 million and expects Q1 2026 revenue of USD 9 million to USD 9.5 million as it emphasizes recurring patient sources and reduces reliance on advertising-driven revenue.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/MYO\">Myomo Inc.</a> published the original content used to generate this news brief via Business Wire (Ref. ID: 202603091606BIZWIRE_USPR_____20260309_BW467133) on March 09, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MYO","symbol_name":"Myomo Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nNDL5Zj5Vb:1","article_id":"2618674366","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2618674366","pubTimestamp":1773086829,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Myomo reported Q4 revenue of USD 11.35 million, down 6%, reflecting a modest decrease in revenue units and a lower average selling price. Q4 operating loss was USD 2.77 million and net loss was USD 3.81 million. FY 2025 revenue rose 26% to USD 40.93 million, while FY net loss was USD 15.57 million. Q4 operating expenses increased 19% to USD 10.56 million, driven primarily by higher sales, clinical and marketing spending, including higher advertising expense. Myomo introduced FY 2026 revenue guidance of USD 43 million to USD 46 million and expects Q1 2026 revenue of USD 9 million to USD 9.5 million as it emphasizes recurring patient sources and reduces reliance on advertising-driven revenue.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MYO":"Myomo Inc.","BK4082":"医疗保健设备"},"translate_title":"Myomo第四季度净亏损扩大至381万美元，运营费用增长19%至1056万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MYO":0.9},"content_text":"Myomo Q4 net loss widens to USD 3.81 million as operating expenses rise 19% to USD 10.56 million\n    \n\n        Myomo reported Q4 revenue of USD 11.35 million, down 6%, reflecting a modest decrease in revenue units and a lower average selling price. Q4 operating loss was USD 2.77 million and net loss was USD 3.81 million. FY 2025 revenue rose 26% to USD 40.93 million, while FY net loss was USD 15.57 million. Q4 operating expenses increased 19% to USD 10.56 million, driven primarily by higher sales, clinical and marketing spending, including higher advertising expense. Myomo introduced FY 2026 revenue guidance of USD 43 million to USD 46 million and expects Q1 2026 revenue of USD 9 million to USD 9.5 million as it emphasizes recurring patient sources and reduces reliance on advertising-driven revenue.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Myomo Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202603091606BIZWIRE_USPR_____20260309_BW467133) on March 09, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2618674366","isCrawlerRequest":true}